Answers are grounded in this paper and cite their sources.
Introduction: Anti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and tolerability and support within-class switching for patients with suboptimal response to a prior anti-CD20 mAb. Patients and methods: This is a retrospective case series of 7 individuals with MS treated in private practice or at an MS clinic who switched to ublituximab from a different anti-CD20 mAb therapy due to efficacy or tolerability concerns. Case descriptions: Details of each case, including clinical and/or radiological outcomes on initial anti-CD20 mAb therapy, reasons for switching, and outcomes after starting ublituximab therapy are provided. Discussion: These cases highlight suboptimal B-cell depletion, inadequate MS disease control, and/or tolerability concerns in people with MS who had clinical improvements or stabilization of disease following a switch from ocrelizumab or rituximab to ublituximab. Conclusion: Within-class switching from a prior anti-CD20 mAb therapy to ublituximab is feasible and may improve outcomes in some people with MS.
No takes yet. Share an insight, caveat, or question.
Berkovich et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: